A Phase 1 Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma

Trial Overview

Am I Eligible?

Participating US Centers

Abramson Cancer Center
University of Pennsylvania

This center is currently accepting patients.

Philadelphia, PA


Roger Williams Medical Center

This center is currently accepting patients.

Providence, RI

ACCEPTING

This trial is currently open and accepting patients.



Additional Information
Trial Phase

Phase 1

Trial Enrollment

72 sparks required

Trial Sponsors
  • Sorrento Therapeutics, Inc.
Trial Identifiers

Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST

;